MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Year: 2019
Type: article
DOI: 10.1530/eje-19-0566
Authors: Michael A Nauck, Juris J Meier
Institutions: St. Josef-Hospital, Ruhr University Bochum
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, semaglutide, dulaglutide, albiglutide, lixisenatide, oral semaglutide, pharmacokinetics, glycemic control, weight loss, cardiovascular outcomes, major adverse cardiovascular events, cardiovascular mortality, heart failure, pre-existing cardiovascular disease
Open Access status: closed
OpenAlex ID: W2979558564
